RELATED ARTICLES

Share this article

He said: 'These results are exciting because they were similar to those of drugs that are used to prevent migraine.

'But often those drugs have many side effects and frequently they are bad enough that people decide to quit taking the drug.'

Scroll down for video

The band delivers electrical impulses to the supraorbital nerve that controls sensation in and around the eye

Prof Schoenen said the results are exciting because they were similar to those of drugs that are used to prevent migraine

In the study 67 people who had an average of four migraine attacks a month were followed for four weeks with no treatment.

Then they received either the stimulation 20 minutes a day for three months or a sham device where the electric impulses delivered were at levels too low to have any effect.

Star Trek's Lt Geordi La Forge: A similar band has been developed to treat migraines

Those given the stimulation had fewer migraine days in the third month compared to the first - falling from seven to five while there was no change for those given the dummy.

The study also found 38 per cent for those who had the stimulation saw their symptoms halve compared to 12 per cent in the control group.

Around one in four women and one in 12 men experience migraines which can be set off by alcohol, stress, fluorescent lighting and foods such as chocolate, red wine and caffeine.

The World Health Organisation rates migraines as a major cause of disability worldwide and it has been estimated to be the most costly neurological disorder in Europe.

Some researchers have linked them to hormonal changes while others have argued a fall in air pressure reduces the amount of oxygen in the blood.

Lower oxygen levels may cause blood vessels in the brain to dilate - triggering a persistent pain. It has also been speculated a drop in pressure affects the fluid protecting the brain inside the skull - leading to increased pressure on brain tissue.

The device, known as Cefaly, is CE marked and costs around £260. It has been submitted to the FDA in the U.S but has not yet been approved.

The study was published in the journal Neurology by the American Academy of Neurology.